FindTrial
Sign In

PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523928-52-00
Enrollment
6
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hypoparathyroidism

Brief summary

At Week 26, proportion of participants with: Albumin-adjusted serum calcium within the normal range measured within 4 weeks prior to and on the Week 26 visit; and, Independence from active vitamin D and, Independence from therapeutic doses of calcium. Calcium ≤600 mg/day (in the form of tablets, powder, liquid suspension, or transdermal patch) is considered as “supplemental” to meet recommended daily intake for general health, as opposed to a “therapeutic” dose to treat hypoparathyroidism

Interventions

DRUGYorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen
DRUGYorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen
DRUGYorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen

Sponsors

Ascendis Pharma Bone Diseases A/S
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
At Week 26, proportion of participants with: Albumin-adjusted serum calcium within the normal range measured within 4 weeks prior to and on the Week 26 visit; and, Independence from active vitamin D and, Independence from therapeutic doses of calcium. Calcium ≤600 mg/day (in the form of tablets, powder, liquid suspension, or transdermal patch) is considered as “supplemental” to meet recommended daily intake for general health, as opposed to a “therapeutic” dose to treat hypoparathyroidism—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 11, 2026